CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients With Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02689453
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:41.038225+00:00
Published At: 2022-04-29T00:00:00+00:00
Record Updated At: 2022-04-29
Results Posted At: 2022-04-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["T-Cell Lymphoma Relapsed", "Adult T-Cell Leukemia (ATL)", "Peripheral T-Cell Lymphoma (PTCL)", "Cutaneous T Cell Lymphoma (CTCL)", "T-Cell Prolymphocytic Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-04-29"
protocolSection.identificationModule.nctId: "NCT02689453"
protocolSection.identificationModule.officialTitle: "A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients With Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-04-29"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.